Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Collaborators, Affiliations

Collaborators

BioBank Japan Cooperative Hospital Group:
Rai Shimoyama¹¹, Koichi Maekawa¹¹, Kiyoshi Kaneko¹¹, Hiromasa Harada¹¹, Shiro Minami¹², Hiroyuki Takei¹², Mitsue Saito¹³, Yasuhisa Terao¹³, Satoru Takeda¹³, Satoshi Asai¹⁴, Mitsuhiko Moriyama¹⁴, Yasuo Takahashi¹⁴, Tomoaki Fujioka¹⁵, Wataru Obara¹⁵, Seijiro Mori¹⁶, Hideki Ito¹⁶, Satoshi Nagayama¹⁷, Yoshio Miki¹⁷, Akihide Masumoto¹⁸, Akira Yamada¹⁸, Yasuko Nishizawa¹⁹, Ken Kodama¹⁹, Hajime Abe²⁰, Tomoharu Shimizu²⁰, Yukihiro Koretsune²¹, Norikazu Masuda²¹, Yasutaka Takeda²²

Affiliations

¹ Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
² Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
³ Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁴ Department of Health Sciences, University of Yamanashi, Yamanashi, Japan.
⁵ Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
⁶ Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
⁷ Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁸ Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
⁹ RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
¹⁰ Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA.
¹¹ Tokushukai Hospitals, Japan.
¹² Nippon Medical School, Japan.
¹³ Juntendo University, Japan.
¹⁴ Nihon University, Japan.
¹⁵ Iwate Medical University, Japan.
¹⁶ Tokyo Metropolitan Institute of Gerontology, Japan.
¹⁷ The Cancer Institute Hospital of JFCR, Japan.
¹⁸ Aso Iizuka Hospital, Japan.
¹⁹ Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
²⁰ Shiga University of Medical Science, Japan.
²¹ National Hospital Organization, Osaka National Hospital, Japan.
²² Fukujuji Hospital, Japan.
²³ Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan. Electronic address: tamaa@med.hokudai.ac.jp.

PMID: 28223083
PMCID: PMC5350586
DOI: 10.1016/j.je.2016.12.009

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Koshi Nakamura et al. J Epidemiol. 2017 Mar.

. 2017 Mar;27(3S):S58-S64.

doi: 10.1016/j.je.2016.12.009. Epub 2017 Feb 20.

Authors

Collaborators

BioBank Japan Cooperative Hospital Group:
Rai Shimoyama¹¹, Koichi Maekawa¹¹, Kiyoshi Kaneko¹¹, Hiromasa Harada¹¹, Shiro Minami¹², Hiroyuki Takei¹², Mitsue Saito¹³, Yasuhisa Terao¹³, Satoru Takeda¹³, Satoshi Asai¹⁴, Mitsuhiko Moriyama¹⁴, Yasuo Takahashi¹⁴, Tomoaki Fujioka¹⁵, Wataru Obara¹⁵, Seijiro Mori¹⁶, Hideki Ito¹⁶, Satoshi Nagayama¹⁷, Yoshio Miki¹⁷, Akihide Masumoto¹⁸, Akira Yamada¹⁸, Yasuko Nishizawa¹⁹, Ken Kodama¹⁹, Hajime Abe²⁰, Tomoharu Shimizu²⁰, Yukihiro Koretsune²¹, Norikazu Masuda²¹, Yasutaka Takeda²²

Affiliations

¹ Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
² Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
³ Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁴ Department of Health Sciences, University of Yamanashi, Yamanashi, Japan.
⁵ Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
⁶ Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
⁷ Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁸ Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
⁹ RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
¹⁰ Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA.
¹¹ Tokushukai Hospitals, Japan.
¹² Nippon Medical School, Japan.
¹³ Juntendo University, Japan.
¹⁴ Nihon University, Japan.
¹⁵ Iwate Medical University, Japan.
¹⁶ Tokyo Metropolitan Institute of Gerontology, Japan.
¹⁷ The Cancer Institute Hospital of JFCR, Japan.
¹⁸ Aso Iizuka Hospital, Japan.
¹⁹ Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
²⁰ Shiga University of Medical Science, Japan.
²¹ National Hospital Organization, Osaka National Hospital, Japan.
²² Fukujuji Hospital, Japan.
²³ Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan. Electronic address: tamaa@med.hokudai.ac.jp.

PMID: 28223083
PMCID: PMC5350586
DOI: 10.1016/j.je.2016.12.009

Abstract

Background: Breast cancer is currently the most common type of cancer in Japanese females. Unlike most other types of cancer, breast cancer develops more frequently in middle-aged females than in elderly females.

Methods: Of all Japanese female breast cancer patients aged ≥20 years whom the BioBank Japan Project originally enrolled between 2003 and 2008, 2034 were registered within 90 days after their diagnosis. We described the lifestyle and clinical characteristics of these patients at study entry. Furthermore, we examined the effect of these characteristics on all-cause mortality.

Results: In the female patients registered within 90 days after diagnosis, the frequency of stage 0 or unclassified, stage I, II, III and IV were 11.4%, 47.9%, 37.0%, 2.9% and 0.8%, respectively. The proportion of histological types was 12.9% for non-invasive carcinoma (ductal carcinoma and lobular carcinoma), 81.0% for invasive carcinoma (papillotubular carcinoma, solid tubular carcinoma, scirrhous carcinoma and special types), 0.2% for Paget's diseases and 5.8% for others. Those positive for the estrogen and progesterone receptors accounted for 75.8% and 62.1% of all patients, respectively. Among 1860 female participants registered within 90 days, 218 participants died during 144,54 person-years of follow-up. More advanced stage, elevation of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels and absence of the estrogen receptor at study entry were crudely associated with an increased risk of all-cause mortality after adjustment for age.

Conclusions: This study showed the association of several clinical characteristics with all-cause mortality in female breast cancer patients.

Keywords: Breast cancer; Histological type; Hormone receptor; Mortality; Stage.

PubMed Disclaimer

Figures

**Fig. 1**
Distribution of the female breast cancer patients according to age at study entry. Bars colored in black, gray and white represent patients in the BioBank Japan (BBJ) Project: () the overall participants and () those registered within 90 days after their diagnosis and () patients in the Patient Survey in Japan, 2005, respectively.

formula image — **Fig. 1**
Distribution of the female breast cancer patients according to age at study entry. Bars colored in black, gray and white represent patients in the BioBank Japan (BBJ) Project: () the overall participants and () those registered within 90 days after their diagnosis and () patients in the Patient Survey in Japan, 2005, respectively.

See this image and copyright information in PMC

References

1. Global Burden of Disease Cancer Collaboration The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527. - PMC - PubMed
1. Ferlay J., Soerjomataram I., Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
1. Katanoda K., Hori M., Matsuda T. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401. - PubMed
1. Ministry of Health, Labour and Welfare, Japan . 2014. National Health and Nutrition Survey in Japan.http://www.e-stat.go.jp/SG1/estat/GL08020103.do?_toGL08020103_&listID=00... Accessed 25 July 2016 [in Japanese]
1. Iwasaki M., Otani T., Inoue M., Sasazuki S., Tsugane S., Japan Public Health Center-Based Prospective Study Group Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. Ann Epidemiol. 2007;17:304–312. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Collaborators

Affiliations

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Authors

Collaborators

Affiliations

Abstract

Figures

References

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical